ECO 2026 12 - 15 May 2026

OASIS 4: Efficacy of Oral Semaglutide 25 mg in Obesity Treatment Targets and Low-risk Outcomes for Cardiometabolic Risk Factors

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.

Keywords

Obesity

Congress poster

GLP-1 RA

Semaglutide (oral)

PHASE 3 (RCT)

Are you a healthcare professional?